Previous 10 | Next 10 |
Promotions of Sara Klymkowsky, Brienne Kugler and Alessandra Sassun NEW YORK, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the expansion of its senior leadership team. This expansion highlights Royalty Pharma’s success in developing a talented, ...
NEW YORK, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 5 th Annual HealthCONx Virtual Conference on November 30, 2022 at 10:30 a.m. ET. The webcast will be accessible ...
Summary Royalty Pharma has 40 projects in the late stages of development. The company's high profitability margins help drive earnings growth. Royalty's reasonable valuation and strong expected growth are likely to drive the stock to outperform. Royalty Pharma's stock is l...
Olpasiran is an siRNA therapeutic being developed by Amgen to reduce risk of cardiovascular disease Arrowhead retains rights to $400 million in development, regulatory and sales milestone payments potentially due from Amgen from the 2016 out licensing agreement NEW YORK an...
- Olpasiran is an siRNA therapeutic being developed by Amgen to reduce risk of cardiovascular disease - Arrowhead retains rights to $400 million in development, regulatory, and sales milestone payments potentially due from Amgen from the 2016 out licensing agreement Arrowhead ...
The following slide deck was published by Royalty Pharma plc in conjunction with their 2022 Q3 earnings call. For further details see: Royalty Pharma plc 2022 Q3 - Results - Earnings Call Presentation
Royalty Pharma plc (RPRX) Q3 2022 Results Earnings Conference Call November 8, 2022, 08:00 AM ET Company Participants George Grofik - SVP, Head, IR & Communications Pablo Legorreta - Founder and Chief Executive Officer Marshall Urist - Executive Vice Presiden...
Royalty Pharma press release ( NASDAQ: RPRX ): Q3 Revenue of $573M (-2.2% Y/Y) misses by $37.32M . Adjusted EBITDA grew 3% to $548 million in the third quarter of 2022. Adjusted Cash Flow increased 26% to $441 million in the third quarter of 2022. Net cash ...
Net cash provided by operating activities (GAAP) of $539 million and Adjusted Cash Receipts ( 1) (non-GAAP) of $597 million Announced transactions of up to $3.0 billion year-to-date, including $1.7 billion in upfront payments Increased 2022 gu...
Summary Baillie Gifford’s 13F portfolio value decreased from ~$97.51B to ~$96.99B this quarter. They increased Shopify, Roblox, Zoom Video, and Twilio while reducing Albemarle Corporation and Li Auto ADR. The top three positions are Tesla Motors, Moderna, and MercadoLib...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Molly Sawaya as Executive Vice President, Head of Human Capital. Molly joins Royalty Pharma from Hudson Bay Capital, where she was a Managing Director and Head of Colleague Experie...
2024-07-24 08:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 ...